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Abstract
Background: The use of HCV-positive livers for HCV-positive recipients is becoming more common. Our aim is to
evaluate long-term outcomes in liver transplant recipients transplanted with HCV antibody-positive organs.
Methods: From the Scientific Registry of Transplant Recipients (1995–2013), we selected all adult liver transplant
recipients with HCV, and cross-sectionally compared long-term graft loss and mortality rates between those who
were transplanted from HCV antibody-positive (HCV+) vs. HCV antibody-negative donors.
Results: We included 33,668 HCV+ liver transplant recipients (54.0 ± 7.7 years old, 74.1% male, 71.0% white, 23.6%
with liver malignancy). Of those, 5.7% (N = 1930) were transplanted from HCV+ donors; the proportion gradually
increased from 2.9% in 1995 to 9.4% in 2013. Patients who were transplanted from HCV+ positive donors were
more likely to be discharged alive after transplantation (95.4% vs. 93.9%, p = 0.006), but this difference was completely
accounted for by a greater proportion of HCV+ donors in more recent study years (p = 0.10 after adjustment for the
transplant year). After transplantation, both mortality in HCV patients transplanted from HCV+ donors (12.5% in 1 year,
24.2% in 3 years, 33.0% in 5 years) and the graft loss rate (2.2% in 1 year, 4.8% in 3 years, 7.5% in 5 years) were similar to
those in HCV patients transplanted from HCV-negative donors (all p > 0.05).
Conclusions: Over the past two decades, the use of HCV+ organs for liver transplantation has tripled. Despite this, the
long-term outcomes of HCV+ liver transplant recipients transplanted from HCV+ donors were not different from those
who were transplanted with HCV-negative organs.
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Background
Chronic hepatitis C infection is currently the most com-
mon indication for liver transplantation in the U.S. [1].
After the disease progresses to its most advanced stages
which include hepatocellular carcinoma and liver failure,
the only alternative to liver-related death is receiving a
liver transplant. Since the progression rate increases with
age [2], and given that the highest prevalence of HCV
infection in the U.S. has been reported in the baby
boomer population [3] who are currently between 50
and 70 years of age, the need for liver transplantation in
HCV-infected patients is likely to remain high in the
coming years. It is unclear whether the recently ap-
proved direct-acting antiviral (DAA) regimens for HCV,
for which their high efficacy and minimal contraindica-
tions are at this point counter-balanced by access-
related barriers [4–6], are able to reverse this trend at
the national level any time soon.
Due to the shortage of organs, the use of HCV-
infected grafts has long been considered as a potentially
viable alternative for patients who are already infected
with HCV. Although concerns about the presence of
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HCV-related damage to the graft and about viral trans-
mission initially seemed plausible, in the last two de-
cades, an increasing number of centers have adopted the
practice of extending their criteria to include HCV-
positive donors for using in HCV-positive recipients. As
of now, the results reported from both single-center and
multi-center studies have been largely consistent about
the lack of an additional risk to a recipient associated
with the presence of HCV infection in a graft, given that
both a recipient and a donor meet other selection cri-
teria [7–11]. It is important to note that most of these
studies had a relatively short follow-up. On the other
hand, the results reported from other multi-center stud-
ies have suggested that the use of HCV-positive donors
is not truly risk-free and may, in fact, result in an add-
itional clinical burden which includes an increased risk
of developing advanced post-transplant fibrosis and
more rapid recurrence of hepatitis in the graft [12, 13].
It is unclear whether this burden could eventually trans-
late into compromised long-term outcomes with long
enough follow-up.
The aim of this study is to report post-transplant out-
comes in HCV-positive recipients transplanted from
HCV-positive donors, and to evaluate the risk for mor-
tality and graft loss associated with the use of HCV-
positive donors, using the most recent long-term




This study used data from the Scientific Registry of
Transplant Recipients (SRTR). The SRTR data system
includes data on all donor, wait-listed candidates, and
transplant recipients in the U.S., submitted by the mem-
bers of the Organ Procurement and Transplantation
Network (OPTN), and has been described elsewhere.
The Health Resources and Services Administration
(HRSA), U.S. Department of Health and Human Ser-
vices provides oversight to the activities of the OPTN
and SRTR contractors.
In this study, we included all liver transplant recipients
with HCV of at least 18 years of age and older who
underwent liver transplantation between 1995 and 2013
in the U.S. In both recipients and donors, their anti-
HCV serology status was used to define those with and
without HCV (HCV+ and HCV-, respectively). No HCV
RNA testing was reported in SRTR.
The length of hospital stay for patients following liver
transplantation was calculated in days from the date of
transplant to the date of discharge. Inpatient mortality
and history of acute rejection during inpatient stay were
recorded. We also collected information on organ do-
nors that included high risk donors classified by the
CDC criteria, basic demographics and clinical history
(diabetes, cancer), and recorded procurement from a
non-heart beating donor.
The primary outcomes included in this study were in-
patient mortality, post-transplant mortality (calculated
by matching with the Social Security Death Master File,
provided by SRTR), and post-transplant graft failure
(defined as a documented re-transplant or a graft
loss-related cause of death). Patients undergoing re-
transplantation were included in the mortality analysis
with their most recent transplants only.
Liver transplant recipients discharged alive were
followed at 6 and 12 months post-transplant, and then
annually until death, re-transplantation, or loss to
follow-up. Patients with no documented date of death
were presumed alive as of September 1, 2015. The time
to events for survival analysis was calculated from the
date of transplant.
Statistical analysis
The clinico-demographic parameters and outcomes of
liver transplant recipients with HCV+ were compared be-
tween those transplanted from HCV+ and HCV- donors
using a Kruskall-Wallis non-parametric test and a chi-
square test for homogeneity. The association of a donor’s
HCV positivity with time to post-transplant mortality and
graft failure was evaluated by a Cox proportional hazard
model with adjustment for clinical and demographic pa-
rameters of both donors’ and recipients’ and for immuno-
suppressant medications used in follow-up. P-values of
0.05 or lower were considered statistically significant. All
analyses were run in SAS 9.3 (SAS Institute, Cary, NC).
For this study, a data use agreement with SRTR was
signed, and a permission to publish the manuscript was
obtained. The study was granted a non-human subject
research exemption by Inova Institutional Review Board.
Results
There were 106,427 liver transplants conducted between
1995 and 2013 included in SRTR. Of those, 95,710 were
in individuals of at least 18 years of age, and in 75,469 of
those the HCV status of a recipient, the HCV status of a
donor, and a recipient’s mortality status were available.
Of this subpopulation, 33,668 (44.6%) liver transplant re-
cipients were HCV+.
There was a substantial increase in the proportion of
HCV+ recipients being transplanted from HCV+ donors
during the study years. Indeed, the increase in less than
20 years was more than three-fold, from less than 3% in
1995 to more than 9% in 2013. The greatest change in
the trend happened in 2010 which resulted in a nearly
50% increase in the proportion of HCV+ donors used
for transplantation in the following 3 years, by at least
10% annually (Fig. 1).
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Comparison of clinico-demographic parameters of
HCV+ liver transplant recipients transplanted from
HCV+ and HCV- donors is included in Table 1. There
was a greater proportion of African-American patients
receiving HCV+ transplants, as well as more patients
with pre-transplant type 2 diabetes, liver cancer, and a
greater proportion of re-transplants (all p < 0.05)
(Table 1). Despite this, patients transplanted with
HCV+ organs had lower MELD scores both with and
without adjustment for the presence of liver cancer
(both p < 0.0001).
The HCV+ donors were, on average, older, less fre-
quently non-heart-beating at the time of procurement,
and were substantially more frequently classified as high
risk (all p < 0.0001). There was no difference in donors’
gender and history of diabetes or cancer (all p > 0.05)
(Table 1).
The short-term outcomes of HCV+ liver transplant re-
cipients were more favorable in those transplanted from
HCV+ donors, including a lower rate of inpatient acute
rejection events and inpatient mortality, and a shorter
inpatient stay (all p < 0.007) (Table 1). However, when
adjusted for the year of transplant, no difference in any
of those outcomes was found (all p > 0.10).
Long-term outcomes were similar in patients trans-
planted from HCV+ and HCV- donors (Table 1, Fig. 2).
Indeed, a borderline significant difference was observed
for 1 and 2 years post-transplant mortality (1 year: 12.5%
in patients transplanted from HCV+ donors vs. 14.1% in
patients with HCV- donors, p = 0.059; 2 years: 18.4% vs.
20.2%, p = 0.054) which was again completely explained
out by the bias in the year of transplant (both p > 0.21
after adjustment for year). At the same time, the follow-
ing years after transplantation revealed nearly identical
mortality rates (all p > 0.5).
Similarly, the graft loss rates were insignificantly lower
in patients transplanted from HCV+ donors up to 3 years
post-transplant (2.2% vs. 2.8% at 1 year, p = 0.15; 3.6% vs.
4.5% at 2 years, p = 0.090; 4.8% vs. 5.9% at 3 years, p =
0.089) due the yearly distribution of HCV+ donors (all
p > 0.13 after adjustment for year).
In a Cox proportional hazard model, after adjust-
ment for the year of transplant, recipient’s age, gender,
race, elements of medical history, MELD score, do-
nor’s age and medical history, and the use of immuno-
suppressant medications, the association of a donor’s
HCV+ status with post-transplant graft loss and mor-
tality in HCV+ liver transplant recipients was highly
insignificant: adjusted hazard ratio (aHR) (95% CI) = 1.045
(0.954–1.145) for time to post-transplant mortality,
aHR = 0.922 (0.727–1.169) for time to graft loss (both
p > 0.33) (all mortality and graft loss predictors tested
in the Cox proportional hazard models are included
in Additional file 1: Table Table S1). Furthermore, the
lack of association of donors’ HCV positivity with the
studied outcomes was also confirmed in a separate
round of case–control analysis where the outcomes of
patients transplanted from HCV+ donors were com-
pared to those of propensity score-matched controls
(all p > 0.15) (Additional file 2: Table S2). In contrast,
a more recent year of transplant was a major pre-
dictor of both lower mortality rate (aHR = 0.963
(0.956–0.971) per year) and lower graft failure rate
(aHR = 0.950 (0.934–0.967) per year) (both p < 0.0001)
even after adjustment for the type of immunosuppres-
sants used in follow-up (Additional file 2: Table S2).
Discussion
In this study, we reported post-transplant outcomes in pa-
tients with HCV transplanted from HCV antibody-
positive donors and compared these outcomes to those of
HCV patients transplanted from HCV-negative donors
using 20 years of data from the nationwide transplant
registry. Our study shows that there are no differences in
Fig. 1 The proportion of HCV+ donors used for transplantation in HCV+ recipients by year
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both short- and long-term outcomes between patients
who were transplanted from HCV-positive and HCV-
negative donors. This is largely consistent with prior re-
ports of similar findings reported from smaller studies
with shorter follow-up.
This finding provides an additional support to the
practice of using HCV-positive donors for HCV-positive
recipients which has become nearly universal in multiple
transplant centers. Indeed, we have shown that the use
of HCV-positive organs has tripled over less than two
decades. Nevertheless, our data confirm that the
medium-term outcomes of patients with HCV are
similar regardless of HCV positivity of the organs. Fur-
thermore, the short-term outcomes, including being dis-
charged alive from the hospital, having a rejection
episode before discharge, and 1 year mortality, all seem
to be lower in HCV-positive organ recipients. This su-
perior short-term survival, in addition to the impact of a
greater proportion of patients receiving HCV-positive
organs in the most recent study years, may also be re-
lated to less advanced liver disease in these patients sug-
gesting a cautious use of HCV-positive organs. Indeed,
patients receiving HCV-positive organs had lower MELD
scores which remained true even after excluding those
Table 1 Comparison of HCV+ liver transplant recipients, donors and outcomes in transplantations from HCV+ and HCV-donors
HCV+ donor HCV- donor P
N 1930 31,738
Recipients:
Age, years 55.1 ± 7.2 53.9 ± 7.7 <0.0001
Male gender 1448 (75.0%) 23,508 (74.1%) 0.35
Race/ethnicity: Caucasian 1346 (69.7%) 22,575 (71.1%) 0.19
Race/ethnicity: African-American 267 (13.8%) 3249 (10.2%) <0.0001
Race/ethnicity: Hispanic 254 (13.2%) 4664 (14.7%) 0.06
Co-infected with HBV (HBV sAg+) 51 (2.7%) 959 (3.1%) 0.32
Pre-transplant history of type 2 diabetes 236 (13.3%) 3335 (11.7%) 0.0441
Liver cancer 544 (28.2%) 7414 (23.4%) <0.0001
Liver re-transplant 3 (0.2%) 6 (0.0%) 0.0004
MELD score 18.2 ± 8.3 20.3 ± 9.7 <0.0001
MELD score excl. liver cancer 19.9 ± 8.3 22.4 ± 9.5 <0.0001
Donors:
Age, years 42.0 ± 11.8 39.6 ± 16.4 <0.0001
Male gender 1196 (62.0%) 19,513 (61.5%) 0.67
Non-heart-beating 31 (1.6%) 1138 (3.6%) <0.0001
History of diabetes 167 (8.7%) 2491 (7.9%) 0.19
History of cancer 39 (2.0%) 834 (2.6%) 0.11
History of high risk behavior 808 (42.4%) 2044 (6.5%) <0.0001
Heterotopic transplant 2 (0.1%) 35 (0.1%) 0.95
Outcomes:
Acute rejection episodes before discharge 36 (2.4%) 809 (4.1%) 0.0020
Discharged alive 1842 (95.4%) 29,808 (93.9%) 0.0063
Length of inpatient stay, days 15.7 ± 20.3 16.4 ± 21.9 0.0013
Mortality: 1 year 242 (12.5%) 4467 (14.1%) 0.059
Mortality: 3 years 399 (24.2%) 7190 (24.8%) 0.58
Mortality: 5 years 424 (33.0%) 8028 (32.5%) 0.68
Mortality: 10 years 281 (47.5%) 7019 (48.6%) 0.59
Graft failure: 1 year 38 (2.2%) 782 (2.8%) 0.15
Graft failure: 3 years 63 (4.8%) 1375 (5.9%) 0.09
Graft failure: 5 years 70 (7.5%) 1465 (8.1%) 0.56
Graft failure: 10 years 50 (13.9%) 1160 (13.5%) 0.86
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who received MELD exclusion for hepatocellular carcin-
oma (HCC).
While there seems to be no evidence supporting the
presence of an increased risk of post-transplant mortality
and allograft losses arisen solely from the HCV-positivity
of a donor, this finding should be interpreted with cau-
tion. In particular, it is necessary to understand that he-
patocytes in an HCV-positive graft might still have been
injured by chronic inflammation, so a careful selection
of both grafts and recipients will be important [13].
Nevertheless, it is interesting to note that in our study,
we have failed to find any evidence of an increased risk
of adverse post-transplant outcomes associated with
being HCV-positive in the group of donors age 45 or
older or in the donors with history of type 2 diabetes
(all p > 0.05).
With the new DAAs becoming more widely available,
the utility of HCV-seropositive organs becomes even
more important. Indeed, we suggest that the use of
HCV-positive organs in HCV-positive recipients who
can be safely and effectively treated post-transplant will
become increasingly a viable option. However, it is im-
portant to note that although preliminary studies have
shown notable benefits of treating post-transplant HCV
patients with DAAs [14, 15], long-term data is still not
available.
The study did have a limitation related to the lack of
HCV RNA results for the donors, so the impact of active
viremia in both donors and recipients could not be eval-
uated, while it is reasonable to believe that such impact
may exist. We also did not have access to histology data
for the grafts so the risk associated with the presence
and/or degree of hepatic steatosis and fibrosis in an allo-
graft could not be studied. The outcomes were limited
to mortality and graft loss only, while other clinical out-
comes, such as developing hepatic inflammation and
fibrosis, could also significantly affect patients’ well-
being in the post-transplant period.
Conclusions
In this study which used the most recent nationwide regis-
try of liver transplant recipients, we have found no evi-
dence of an increased risk for adverse post-transplant
outcomes that could be associated with HCV positivity of
a donor. Therefore, we postulate that while we, as a soci-
ety, are working on decreasing wait-list mortality in liver
transplant candidates, HCV-positive allografts could be a
reasonably safe option for patients with chronic HCV in-
fection who are in need of a liver transplant. It is import-
ant to note that our data cannot be used in support of
indiscriminate use of HCV-positive donors, especially
those who are HCV RNA-positive, given previously re-
ported unfavorable histologic outcomes which could not
be ruled out in this study. Further studies are needed to
establish evidence-based selection criteria for HCV-
positive donors which could provide patients with the best
possible risk-to-benefit ratio.
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Fig. 2 Post-transplant survival in HCV+ liver transplant recipients transplanted from HCV+ and HCV- donors. P > 0.05 at all time points. aHR –
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